| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.542 | 0.008 | 0.767 | Anticoagulant | 0.428 0.014 DBMET02968 0.483 0.011 DBMET02969 0.767 0.004 DBMET02970 | DBMET02970 | |
| 0.455 | 0.015 | 0.493 | Interleukin 2 agonist | 0.429 0.02 DBMET02968 0.493 0.009 DBMET02969 0.361 0.041 DBMET02970 | DBMET02969 | |
| 0.476 | 0.037 | 0.476 | Toll-Like receptor agonist | 0.405 0.058 DBMET02968 0.326 0.095 DBMET02969 | ||
| 0.476 | 0.037 | 0.476 | Toll-Like receptor 7 agonist | 0.406 0.057 DBMET02968 0.308 0.105 DBMET02969 | ||
| 0.442 | 0.004 | 0.442 | Ca(v)3.3 blocker | 0.38 0.007 DBMET02968 0.241 0.115 DBMET02969 0.363 0.01 DBMET02970 | ||
| 0.449 | 0.015 | 0.449 | Sigma receptor agonist | 0.341 0.032 DBMET02968 0.144 0.09 DBMET02970 | ||
| 0.45 | 0.019 | 0.45 | Superoxide dismutase inhibitor | 0.419 0.024 DBMET02968 0.379 0.03 DBMET02970 | ||
| 0.403 | 0.028 | 0.403 | Cardiotonic | 0.227 0.098 DBMET02968 0.203 0.115 DBMET02969 | ||
| 0.396 | 0.028 | 0.441 | Platelet antagonist | 0.31 0.05 DBMET02968 0.441 0.02 DBMET02969 0.384 0.03 DBMET02970 | DBMET02969 | |
| 0.42 | 0.066 | 0.475 | 5 Hydroxytryptamine release inhibitor | 0.365 0.103 DBMET02968 0.475 0.041 DBMET02969 | DBMET02969 | |
| 0.359 | 0.009 | 0.359 | Nav1.2 sodium channel blocker | 0.211 0.031 DBMET02968 0.18 0.042 DBMET02970 | ||
| 0.361 | 0.015 | 0.429 | Thrombolytic | 0.341 0.018 DBMET02968 0.429 0.009 DBMET02969 0.399 0.011 DBMET02970 | DBMET02969 | |
| 0.332 | 0.01 | 0.332 | Neuropeptide Y2 antagonist | 0.304 0.017 DBMET02968 0.239 0.067 DBMET02970 | ||
| 0.35 | 0.034 | 0.35 | Insulysin inhibitor | 0.32 0.047 DBMET02968 0.185 0.181 DBMET02970 | ||
| 0.336 | 0.033 | 0.428 | Interleukin agonist | 0.284 0.056 DBMET02968 0.428 0.015 DBMET02969 | DBMET02969 | |
| 0.293 | 0.024 | 0.423 | Diuretic | 0.206 0.042 DBMET02968 0.423 0.012 DBMET02969 0.25 0.031 DBMET02970 | DBMET02969 | |
| 0.256 | 0.005 | 0.256 | 5 Hydroxytryptamine 3A agonist | 0.189 0.018 DBMET02968 0.093 0.085 DBMET02970 | ||
| 0.297 | 0.046 | 0.297 | 5 Hydroxytryptamine uptake stimulant | 0.263 0.069 DBMET02968 | ||
| 0.298 | 0.048 | 0.298 | Interleukin antagonist | 0.258 0.059 DBMET02968 0.155 0.114 DBMET02969 | ||
| 0.319 | 0.077 | 0.7 | Antithrombotic | 0.274 0.108 DBMET02968 0.7 0.008 DBMET02969 0.329 0.073 DBMET02970 | DBMET02969 | |
| 0.232 | 0.005 | 0.302 | Thrombin inhibitor | 0.14 0.012 DBMET02968 0.098 0.027 DBMET02969 0.302 0.005 DBMET02970 | DBMET02970 | |
| 0.229 | 0.007 | 0.229 | NMDA 2 receptor antagonist | 0.183 0.011 DBMET02968 0.117 0.025 DBMET02970 | ||
| 0.229 | 0.011 | 0.229 | NMDA receptor antagonist | 0.201 0.014 DBMET02968 0.125 0.033 DBMET02970 | ||
| 0.248 | 0.036 | 0.248 | Insulin sensitizer | 0.232 0.045 DBMET02968 0.243 0.039 DBMET02969 0.145 0.141 DBMET02970 | ||
| 0.227 | 0.025 | 0.227 | Neurotensin receptor agonist | 0.219 0.028 DBMET02968 | ||
| 0.214 | 0.014 | 0.214 | Neuropeptide Y1 antagonist | 0.181 0.029 DBMET02968 | ||
| 0.202 | 0.003 | 0.202 | Diamine oxidase inhibitor | 0.099 0.004 DBMET02968 0.053 0.013 DBMET02970 | ||
| 0.202 | 0.005 | 0.202 | Trypsin inhibitor | 0.132 0.009 DBMET02968 0.07 0.034 DBMET02969 0.138 0.008 DBMET02970 | ||
| 0.214 | 0.019 | 0.214 | Cathepsin H inhibitor | 0.154 0.044 DBMET02968 0.105 0.099 DBMET02970 | ||
| 0.2 | 0.005 | 0.2 | NMDA 2A receptor antagonist | 0.167 0.006 DBMET02968 0.072 0.023 DBMET02970 | ||
| 0.245 | 0.053 | 0.245 | Anesthetic general | 0.193 0.078 DBMET02968 0.19 0.08 DBMET02969 | ||
| 0.214 | 0.028 | 0.214 | Sodium channel blocker | |||
| 0.231 | 0.048 | 0.234 | Nitric-oxide synthase stimulant | 0.22 0.061 DBMET02968 0.234 0.045 DBMET02969 | DBMET02969 | |
| 0.241 | 0.057 | 0.387 | Peptidyltransferase inhibitor | 0.243 0.056 DBMET02968 0.387 0.008 DBMET02969 0.167 0.154 DBMET02970 | DBMET02969 | |
| 0.188 | 0.005 | 0.202 | Neuraminidase (influenza) inhibitor | 0.162 0.006 DBMET02968 0.186 0.005 DBMET02969 0.202 0.005 DBMET02970 | DBMET02970 | |
| 0.187 | 0.004 | 0.187 | Neuraminidase inhibitor | 0.158 0.005 DBMET02968 0.166 0.005 DBMET02969 0.174 0.005 DBMET02970 | ||
| 0.189 | 0.006 | 0.189 | Factor V inhibitor | 0.166 0.012 DBMET02968 0.132 0.029 DBMET02969 0.156 0.016 DBMET02970 | ||
| 0.185 | 0.003 | 0.185 | Epithelial sodium channel blocker | 0.148 0.004 DBMET02968 0.091 0.009 DBMET02969 0.095 0.008 DBMET02970 | ||
| 0.281 | 0.099 | 0.433 | Apoptosis antagonist | 0.256 0.121 DBMET02968 0.433 0.03 DBMET02969 | DBMET02969 | |
| 0.248 | 0.071 | 0.656 | Angiogenesis stimulant | 0.246 0.072 DBMET02968 0.656 0.005 DBMET02969 0.524 0.01 DBMET02970 | DBMET02969 | |
| 0.194 | 0.02 | 0.194 | Nav1.4 sodium channel blocker | 0.174 0.025 DBMET02968 0.102 0.074 DBMET02969 0.17 0.027 DBMET02970 | ||
| 0.196 | 0.022 | 0.196 | Aminopeptidase B inhibitor | 0.17 0.03 DBMET02968 0.168 0.03 DBMET02970 | ||
| 0.178 | 0.005 | 0.178 | Urokinase inhibitor | 0.139 0.008 DBMET02968 0.047 0.034 DBMET02969 0.12 0.012 DBMET02970 | ||
| 0.178 | 0.005 | 0.178 | Alpha 2 adrenoreceptor agonist | 0.096 0.016 DBMET02968 | ||
| 0.291 | 0.122 | 0.291 | GABA C receptor rho-3 antagonist | 0.227 0.177 DBMET02968 | ||
| 0.174 | 0.008 | 0.174 | Neuropeptide agonist | 0.152 0.012 DBMET02968 0.075 0.033 DBMET02969 0.136 0.017 DBMET02970 | ||
| 0.179 | 0.014 | 0.179 | Nitric-oxide synthase inhibitor | 0.099 0.061 DBMET02968 | ||
| 0.17 | 0.005 | 0.221 | NMDA receptor subunit 3B antagonist | 0.221 0.004 DBMET02968 | DBMET02968 | |
| 0.179 | 0.015 | 0.208 | Histidine decarboxylase inhibitor | 0.208 0.012 DBMET02968 | DBMET02968 | |
| 0.201 | 0.039 | 0.201 | Thiol protease inhibitor | 0.135 0.087 DBMET02968 | ||
| 0.203 | 0.042 | 0.203 | Phospholipase C inhibitor | 0.197 0.046 DBMET02968 0.191 0.05 DBMET02969 0.173 0.069 DBMET02970 | ||
| 0.231 | 0.07 | 0.231 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | |||
| 0.172 | 0.012 | 0.172 | Inducible nitric-oxide synthase inhibitor | 0.093 0.044 DBMET02968 0.081 0.061 DBMET02970 | ||
| 0.21 | 0.055 | 0.21 | Growth hormone agonist | 0.193 0.062 DBMET02968 | ||
| 0.158 | 0.007 | 0.158 | Factor VIIa inhibitor | 0.104 0.011 DBMET02968 0.076 0.014 DBMET02970 | ||
| 0.166 | 0.019 | 0.596 | AMP-activated protein kinase stimulant | 0.194 0.012 DBMET02968 0.596 0.003 DBMET02969 | DBMET02969 | |
| 0.21 | 0.063 | 0.403 | Non-steroidal antiinflammatory agent | 0.155 0.109 DBMET02968 0.403 0.013 DBMET02969 | DBMET02969 | |
| 0.156 | 0.01 | 0.156 | Integrin antagonist | 0.07 0.022 DBMET02968 | ||
| 0.226 | 0.088 | 0.226 | Calpain inhibitor | |||
| 0.146 | 0.011 | 0.146 | Histamine H2 receptor antagonist | 0.093 0.043 DBMET02968 | ||
| 0.142 | 0.007 | 0.142 | Protease activated receptor 1 antagonist | 0.085 0.018 DBMET02968 0.054 0.03 DBMET02970 | ||
| 0.152 | 0.018 | 0.152 | Interleukin 2 antagonist | 0.131 0.031 DBMET02968 | ||
| 0.143 | 0.009 | 0.143 | Melanocortin 3 antagonist | 0.039 0.017 DBMET02968 0.026 0.021 DBMET02970 | ||
| 0.165 | 0.032 | 0.165 | Ferrochelatase inhibitor | |||
| 0.14 | 0.007 | 0.14 | Maillard reaction inhibitor | 0.133 0.008 DBMET02968 0.1 0.017 DBMET02969 0.074 0.027 DBMET02970 | ||
| 0.134 | 0.002 | 0.134 | Histamine H2 receptor agonist | 0.083 0.006 DBMET02968 0.07 0.01 DBMET02970 | ||
| 0.16 | 0.028 | 0.163 | Heat shock protein 70 antagonist | 0.151 0.043 DBMET02968 0.163 0.024 DBMET02969 | DBMET02969 | |
| 0.139 | 0.008 | 0.139 | Kallikrein 1 inhibitor | 0.083 0.017 DBMET02968 0.062 0.031 DBMET02969 0.075 0.021 DBMET02970 | ||
| 0.141 | 0.012 | 0.141 | GP IIb/IIIa receptor antagonist | 0.071 0.024 DBMET02968 0.052 0.031 DBMET02970 | ||
| 0.141 | 0.015 | 0.141 | Factor XII inhibitor | 0.117 0.025 DBMET02968 0.099 0.038 DBMET02970 | ||
| 0.15 | 0.025 | 0.15 | HIV-1 integrase (Overall Integration) inhibitor | 0.14 0.029 DBMET02968 | ||
| 0.171 | 0.047 | 0.374 | Cell wall synthesis inhibitor | 0.217 0.024 DBMET02968 0.374 0.007 DBMET02969 0.234 0.019 DBMET02970 | DBMET02969 | |
| 0.126 | 0.004 | 0.126 | Vascular adhesion protein 1 inhibitor | 0.05 0.015 DBMET02968 | ||
| 0.128 | 0.006 | 0.128 | Histamine agonist | 0.047 0.045 DBMET02968 | ||
| 0.126 | 0.005 | 0.126 | Complement C3a chemotactic receptor antagonist | 0.101 0.008 DBMET02968 0.044 0.03 DBMET02969 0.082 0.013 DBMET02970 | ||
| 0.127 | 0.01 | 0.127 | Plasminogen activator inhibitor | 0.103 0.015 DBMET02968 0.087 0.021 DBMET02970 | ||
| 0.182 | 0.065 | 0.182 | Succinate dehydrogenase inhibitor | 0.182 0.065 DBMET02968 | ||
| 0.117 | 0.003 | 0.117 | Sodium/hydrogen exchanger inhibitor | 0.046 0.004 DBMET02968 0.019 0.01 DBMET02969 0.06 0.003 DBMET02970 | ||
| 0.119 | 0.005 | 0.119 | Trypsin I inhibitor | 0.07 0.008 DBMET02968 0.05 0.012 DBMET02970 | ||
| 0.218 | 0.105 | 0.225 | Tyrosine 3 hydroxylase inhibitor | 0.225 0.096 DBMET02968 | DBMET02968 | |
| 0.117 | 0.004 | 0.117 | Neuraminidase (Influenza A) inhibitor | 0.09 0.004 DBMET02968 0.096 0.004 DBMET02969 0.066 0.009 DBMET02970 | ||
| 0.149 | 0.037 | 0.149 | Falcipain 3 inhibitor | 0.094 0.076 DBMET02968 | ||
| 0.142 | 0.031 | 0.142 | Potassium channel (Ca-activated) activator | 0.139 0.032 DBMET02968 | ||
| 0.252 | 0.145 | 0.252 | Calcium channel activator | |||
| 0.121 | 0.014 | 0.121 | Plasmin inhibitor | 0.074 0.024 DBMET02968 0.119 0.014 DBMET02970 | ||
| 0.113 | 0.007 | 0.113 | Botulinum neurotoxin type A inhibitor | 0.106 0.008 DBMET02968 | ||
| 0.113 | 0.007 | 0.135 | NMDA receptor subunit 3A antagonist | 0.135 0.005 DBMET02968 | DBMET02968 | |
| 0.117 | 0.011 | 0.117 | Secretase beta inhibitor | 0.075 0.043 DBMET02968 | ||
| 0.118 | 0.012 | 0.118 | Neurotensin receptor antagonist | 0.088 0.016 DBMET02968 0.052 0.027 DBMET02970 | ||
| 0.139 | 0.034 | 0.139 | Nav1.5 sodium channel blocker | |||
| 0.118 | 0.013 | 0.118 | Cathepsin D inhibitor | 0.079 0.025 DBMET02968 0.063 0.033 DBMET02970 | ||
| 0.149 | 0.047 | 0.274 | Cell adhesion inhibitor | 0.097 0.095 DBMET02968 0.274 0.012 DBMET02969 0.264 0.013 DBMET02970 | DBMET02969 | |
| 0.212 | 0.113 | 0.526 | Immunostimulant | 0.184 0.13 DBMET02968 0.526 0.026 DBMET02969 0.186 0.129 DBMET02970 | DBMET02969 | |
| 0.107 | 0.01 | 0.107 | Factor X inhibitor | 0.047 0.023 DBMET02968 0.05 0.022 DBMET02970 | ||
| 0.119 | 0.022 | 0.119 | Glutamate release inhibitor | 0.098 0.046 DBMET02968 0.11 0.03 DBMET02969 | ||
| 0.12 | 0.024 | 0.306 | Cell adhesion molecule inhibitor | 0.073 0.063 DBMET02968 0.168 0.012 DBMET02969 0.306 0.005 DBMET02970 | DBMET02970 | |
| 0.106 | 0.011 | 0.106 | Melanocortin antagonist | 0.058 0.022 DBMET02968 0.049 0.03 DBMET02970 | ||
| 0.105 | 0.011 | 0.105 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.076 0.044 DBMET02968 | ||
| 0.122 | 0.029 | 0.122 | Neuropeptide Y antagonist | |||
| 0.23 | 0.138 | 0.452 | Angiogenesis inhibitor | 0.334 0.078 DBMET02968 0.364 0.065 DBMET02969 0.452 0.04 DBMET02970 | DBMET02970 | |
| 0.129 | 0.037 | 0.131 | Urease inhibitor | 0.131 0.035 DBMET02968 | DBMET02968 | |
| 0.106 | 0.014 | 0.106 | NMDA 2C receptor antagonist | 0.083 0.023 DBMET02968 | ||
| 0.113 | 0.023 | 0.113 | Alpha adrenoreceptor agonist | |||
| 0.183 | 0.095 | 0.183 | Platelet aggregation inhibitor | |||
| 0.105 | 0.018 | 0.105 | Argininosuccinate synthase inhibitor | 0.077 0.026 DBMET02968 0.05 0.046 DBMET02969 | ||
| 0.129 | 0.043 | 0.129 | Nav1.1 sodium channel blocker | 0.092 0.077 DBMET02968 | ||
| 0.104 | 0.019 | 0.104 | Ca(v)3.1 blocker | 0.085 0.046 DBMET02968 | ||
| 0.197 | 0.112 | 0.35 | Tumour necrosis factor alpha release inhibitor | 0.35 0.038 DBMET02969 | DBMET02969 | |
| 0.097 | 0.014 | 0.179 | Factor Xa inhibitor | 0.098 0.014 DBMET02969 0.179 0.007 DBMET02970 | DBMET02970 | |
| 0.088 | 0.005 | 0.088 | Tryptase inhibitor | 0.046 0.015 DBMET02968 0.041 0.02 DBMET02970 | ||
| 0.092 | 0.01 | 0.092 | Sphingosine kinase 2 inhibitor | 0.08 0.015 DBMET02968 | ||
| 0.109 | 0.03 | 0.152 | Cathepsin G inhibitor | 0.071 0.052 DBMET02968 0.152 0.021 DBMET02970 | DBMET02970 | |
| 0.103 | 0.024 | 0.103 | CXC chemokine 4 receptor antagonist | |||
| 0.162 | 0.083 | 0.257 | ATPase inhibitor | 0.257 0.012 DBMET02969 | DBMET02969 | |
| 0.088 | 0.011 | 0.088 | Melanocortin 4 antagonist | 0.056 0.021 DBMET02968 0.044 0.027 DBMET02970 | ||
| 0.146 | 0.072 | 0.379 | Hemostatic | 0.379 0.009 DBMET02969 0.2 0.032 DBMET02970 | DBMET02969 | |
| 0.077 | 0.004 | 0.077 | Histamine H1 receptor agonist | 0.045 0.027 DBMET02968 | ||
| 0.085 | 0.013 | 0.085 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.089 | 0.018 | 0.089 | Protease activated receptor antagonist | 0.064 0.042 DBMET02968 0.056 0.053 DBMET02970 | ||
| 0.126 | 0.054 | 0.126 | Interleukin 8 antagonist | 0.103 0.09 DBMET02968 | ||
| 0.084 | 0.013 | 0.084 | Melanocortin 1 antagonist | 0.047 0.021 DBMET02968 0.033 0.031 DBMET02970 | ||
| 0.083 | 0.014 | 0.083 | Kallikrein inhibitor | 0.044 0.037 DBMET02968 | ||
| 0.07 | 0.005 | 0.07 | Melatonin 3 antagonist | 0.021 0.012 DBMET02968 | ||
| 0.073 | 0.009 | 0.073 | Factor VII inhibitor | 0.037 0.016 DBMET02968 0.031 0.019 DBMET02970 | ||
| 0.073 | 0.01 | 0.073 | Melanocortin 5 antagonist | 0.023 0.021 DBMET02968 | ||
| 0.08 | 0.017 | 0.08 | Bombesin 2 receptor antagonist | 0.058 0.026 DBMET02968 | ||
| 0.068 | 0.006 | 0.068 | Trypsin II inhibitor | 0.044 0.011 DBMET02968 0.046 0.011 DBMET02970 | ||
| 0.124 | 0.062 | 0.124 | Proteasome inhibitor | 0.1 0.088 DBMET02968 | ||
| 0.063 | 0.004 | 0.063 | Histamine H4 receptor agonist | |||
| 0.066 | 0.006 | 0.066 | Thrombin receptor antagonist | 0.03 0.017 DBMET02968 | ||
| 0.144 | 0.086 | 0.28 | Interferon gamma antagonist | 0.146 0.083 DBMET02968 0.28 0.023 DBMET02969 | DBMET02969 | |
| 0.083 | 0.025 | 0.083 | 5 Hydroxytryptamine 3 agonist | |||
| 0.224 | 0.168 | 0.224 | Calpain 2 inhibitor | |||
| 0.287 | 0.231 | 0.287 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.11 | 0.057 | 0.11 | GABA C receptor agonist | 0.093 0.075 DBMET02968 | ||
| 0.154 | 0.102 | 0.368 | Platelet adhesion inhibitor | 0.368 0.016 DBMET02969 0.252 0.049 DBMET02970 | DBMET02969 | |
| 0.084 | 0.032 | 0.084 | Glucagon-like peptide 1 agonist | 0.068 0.043 DBMET02968 | ||
| 0.241 | 0.191 | 0.241 | Analgesic | |||
| 0.074 | 0.024 | 0.074 | Ornithine carbamoyltransferase inhibitor | 0.053 0.037 DBMET02968 | ||
| 0.173 | 0.125 | 0.173 | 5 Hydroxytryptamine 3E antagonist | |||
| 0.083 | 0.036 | 0.083 | GABA B receptor agonist | 0.082 0.038 DBMET02968 | ||
| 0.069 | 0.021 | 0.142 | Factor IXa inhibitor | 0.055 0.031 DBMET02968 0.105 0.009 DBMET02969 0.142 0.004 DBMET02970 | DBMET02970 | |
| 0.059 | 0.011 | 0.059 | VLA-4 antagonist | 0.03 0.017 DBMET02968 | ||
| 0.182 | 0.135 | 0.258 | Spasmolytic | 0.258 0.088 DBMET02969 | DBMET02969 | |
| 0.059 | 0.012 | 0.059 | Melanocortin 1 agonist | |||
| 0.052 | 0.006 | 0.052 | Bradykinin B2 receptor antagonist | 0.046 0.01 DBMET02968 0.038 0.017 DBMET02970 | ||
| 0.071 | 0.025 | 0.071 | Gonadotropin-releasing hormone receptor agonist | 0.061 0.037 DBMET02968 | ||
| 0.071 | 0.025 | 0.071 | Kallikrein 7 inhibitor | 0.06 0.057 DBMET02968 | ||
| 0.057 | 0.012 | 0.057 | Melanocortin agonist | |||
| 0.052 | 0.007 | 0.052 | Bradykinin B2 receptor agonist | 0.04 0.012 DBMET02968 0.03 0.018 DBMET02970 | ||
| 0.099 | 0.055 | 0.106 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.106 0.048 DBMET02969 | DBMET02969 | |
| 0.071 | 0.029 | 0.071 | Cathepsin L inhibitor | |||
| 0.07 | 0.028 | 0.07 | Histone deacetylase SIRT3 inhibitor | |||
| 0.069 | 0.028 | 0.069 | Potassium channel intermediate-conductance Ca-activated blocker | |||
| 0.049 | 0.008 | 0.049 | Lysine carboxypeptidase inhibitor | 0.036 0.012 DBMET02968 | ||
| 0.076 | 0.038 | 0.084 | Potassium channel large-conductance Ca-activated activator | 0.084 0.033 DBMET02968 | DBMET02968 | |
| 0.072 | 0.034 | 0.072 | NMDA receptor glycine site agonist | |||
| 0.041 | 0.004 | 0.041 | Complement factor 1s inhibitor | 0.027 0.013 DBMET02968 0.032 0.006 DBMET02970 | ||
| 0.117 | 0.08 | 0.264 | Cyclooxygenase 3 inhibitor | 0.264 0.008 DBMET02969 | DBMET02969 | |
| 0.051 | 0.015 | 0.081 | Arginase inhibitor | 0.041 0.022 DBMET02968 0.081 0.005 DBMET02969 | DBMET02969 | |
| 0.086 | 0.05 | 0.127 | Adrenaline agonist | 0.127 0.023 DBMET02968 | DBMET02968 | |
| 0.065 | 0.03 | 0.065 | Sphingosine kinase inhibitor | 0.059 0.041 DBMET02968 | ||
| 0.047 | 0.012 | 0.047 | AMPA 1 receptor antagonist | |||
| 0.051 | 0.017 | 0.051 | Integrin alpha5beta1 antagonist | 0.041 0.028 DBMET02968 | ||
| 0.05 | 0.015 | 0.05 | Bradykinin antagonist | |||
| 0.041 | 0.008 | 0.041 | Vitronectin receptor antagonist | |||
| 0.038 | 0.005 | 0.038 | Complement factor 1r inhibitor | 0.03 0.011 DBMET02968 0.029 0.012 DBMET02970 | ||
| 0.049 | 0.016 | 0.064 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.064 0.005 DBMET02968 | DBMET02968 | |
| 0.051 | 0.018 | 0.051 | Thymidine kinase inhibitor | 0.045 0.023 DBMET02970 | ||
| 0.086 | 0.055 | 0.115 | Vanilloid agonist | 0.1 0.033 DBMET02968 0.115 0.021 DBMET02970 | DBMET02970 | |
| 0.045 | 0.015 | 0.045 | VCAM-1 antagonist | 0.041 0.022 DBMET02968 | ||
| 0.045 | 0.015 | 0.045 | VCAM antagonist | 0.041 0.022 DBMET02968 | ||
| 0.103 | 0.073 | 0.119 | Mucolytic | 0.102 0.075 DBMET02968 0.119 0.055 DBMET02969 | DBMET02969 | |
| 0.087 | 0.058 | 0.087 | Histamine N-methyltransferase inhibitor | |||
| 0.041 | 0.013 | 0.041 | Endothelial nitric-oxide synthase inhibitor | |||
| 0.051 | 0.023 | 0.052 | Oxytocin agonist | 0.052 0.023 DBMET02968 | DBMET02968 | |
| 0.041 | 0.013 | 0.041 | Histamine H3 receptor agonist | |||
| 0.04 | 0.013 | 0.04 | Melanocortin 3 agonist | |||
| 0.119 | 0.092 | 0.119 | Histone deacetylase SIRT1 inhibitor | |||
| 0.043 | 0.016 | 0.043 | Somatostatin 5 agonist | 0.032 0.029 DBMET02968 | ||
| 0.051 | 0.025 | 0.126 | Mannosidase inhibitor | 0.042 0.037 DBMET02968 0.126 0.004 DBMET02969 | DBMET02969 | |
| 0.038 | 0.013 | 0.038 | Melanocortin 4 agonist | |||
| 0.061 | 0.036 | 0.061 | 5 Hydroxytryptamine 5 antagonist | |||
| 0.061 | 0.036 | 0.061 | Ca(v)3.2 blocker | |||
| 0.145 | 0.121 | 0.145 | Psychostimulant | |||
| 0.094 | 0.071 | 0.094 | Protease inhibitor | 0.089 0.076 DBMET02968 | ||
| 0.042 | 0.019 | 0.042 | Purinergic P2X7 antagonist | |||
| 0.031 | 0.009 | 0.031 | Integrin beta3 antagonist | |||
| 0.046 | 0.024 | 0.046 | Erythropoietin receptor agonist | 0.042 0.026 DBMET02968 | ||
| 0.079 | 0.058 | 0.088 | Glycine receptor antagonist | 0.088 0.045 DBMET02969 | DBMET02969 | |
| 0.052 | 0.031 | 0.052 | CD45 antagonist | 0.05 0.036 DBMET02968 | ||
| 0.024 | 0.004 | 0.024 | Prokineticin receptor 1 antagonist | 0.02 0.007 DBMET02968 0.018 0.009 DBMET02970 | ||
| 0.083 | 0.064 | 0.083 | Hematopoietic | |||
| 0.067 | 0.047 | 0.067 | Potassium channel (ATP-sensitive) blocker | |||
| 0.036 | 0.017 | 0.036 | Carboxypeptidase B inhibitor | 0.032 0.024 DBMET02968 | ||
| 0.109 | 0.09 | 0.149 | Alpha-N-acetylglucosaminidase inhibitor | 0.149 0.056 DBMET02969 | DBMET02969 | |
| 0.022 | 0.004 | 0.022 | Melatonin 5 antagonist | |||
| 0.062 | 0.044 | 0.062 | NMDA receptor agonist | |||
| 0.082 | 0.064 | 0.082 | Myeloperoxidase inhibitor | |||
| 0.025 | 0.007 | 0.025 | Thymidine kinase (Herpes simplex virus 2) inhibitor | |||
| 0.074 | 0.056 | 0.078 | Analgesic, opioid | 0.078 0.05 DBMET02968 | DBMET02968 | |
| 0.038 | 0.02 | 0.038 | Plasma kallikrein inhibitor | |||
| 0.059 | 0.042 | 0.059 | Carbonic anhydrase stimulant | |||
| 0.022 | 0.006 | 0.022 | Complement factor 1 inhibitor | 0.017 0.013 DBMET02968 0.018 0.012 DBMET02970 | ||
| 0.038 | 0.023 | 0.038 | Glutamate (mGluR3) antagonist | |||
| 0.042 | 0.026 | 0.042 | Acid-sensing ion channel blocker | |||
| 0.092 | 0.079 | 0.092 | Carbonic anhydrase XV inhibitor | 0.088 0.086 DBMET02968 | ||
| 0.036 | 0.023 | 0.036 | Tryptophan 5 hydroxylase inhibitor | |||
| 0.023 | 0.01 | 0.023 | Neuraminidase (Influenza B) inhibitor | 0.02 0.018 DBMET02968 | ||
| 0.174 | 0.162 | 0.314 | DNA synthesis inhibitor | 0.19 0.139 DBMET02968 0.314 0.039 DBMET02969 | DBMET02969 | |
| 0.024 | 0.012 | 0.024 | Integrin beta5 antagonist | |||
| 0.034 | 0.023 | 0.061 | Factor XI inhibitor | 0.061 0.007 DBMET02970 | DBMET02970 | |
| 0.062 | 0.051 | 0.062 | Calcium channel P-type blocker | |||
| 0.103 | 0.093 | 0.103 | Nav1.3 sodium channel blocker | |||
| 0.02 | 0.011 | 0.02 | Protease activated receptor agonist | |||
| 0.027 | 0.017 | 0.027 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.027 0.016 DBMET02970 | ||
| 0.023 | 0.014 | 0.023 | Integrin alphaVbeta3 antagonist | |||
| 0.027 | 0.018 | 0.027 | Antidiuretic hormone agonist | |||
| 0.065 | 0.056 | 0.065 | Exportin-1 inhibitor | |||
| 0.166 | 0.158 | 0.166 | 5 Hydroxytryptamine release stimulant | |||
| 0.08 | 0.073 | 0.092 | Falcipain inhibitor | 0.092 0.061 DBMET02969 | DBMET02969 | |
| 0.047 | 0.041 | 0.047 | Sodium/calcium exchanger inhibitor | |||
| 0.088 | 0.082 | 0.091 | Anabolic | 0.091 0.077 DBMET02968 | DBMET02968 | |
| 0.078 | 0.073 | 0.086 | Estrogen-related receptor beta agonist | 0.086 0.05 DBMET02968 | DBMET02968 | |
| 0.047 | 0.042 | 0.059 | Factor III inhibitor | 0.048 0.04 DBMET02968 0.059 0.019 DBMET02969 | DBMET02969 | |
| 0.038 | 0.035 | 0.038 | Sphingosine kinase 1 inhibitor | |||
| 0.105 | 0.101 | 0.132 | Bone formation stimulant | 0.132 0.074 DBMET02968 0.116 0.089 DBMET02969 | DBMET02968 | |
| 0.021 | 0.018 | 0.021 | Vasopressin 1 agonist | |||
| 0.019 | 0.016 | 0.019 | Melanocortin 5 agonist | |||
| 0.076 | 0.074 | 0.089 | Falcipain 2 inhibitor | 0.089 0.061 DBMET02969 | DBMET02969 | |
| 0.031 | 0.029 | 0.034 | Phosphoglycerate kinase inhibitor | 0.034 0.026 DBMET02968 | DBMET02968 | |
| 0.006 | 0.005 | 0.006 | Integrin alpha5beta6 antagonist | |||
| 0.029 | 0.028 | 0.029 | Calcitonin receptor agonist | |||
| 0.105 | 0.109 | 0.114 | Antibacterial (Helicobacter pylori) | 0.114 0.092 DBMET02970 | DBMET02970 | |
| 0.034 | 0.039 | 0.075 | Factor XIa inhibitor | 0.075 0.009 DBMET02970 | DBMET02970 | |
| 0.09 | 0.098 | 0.107 | DOPA decarboxylase inhibitor | 0.107 0.062 DBMET02968 | DBMET02968 | |
| 0.121 | 0.132 | 0.211 | Melanin inhibitor | 0.137 0.102 DBMET02968 0.211 0.037 DBMET02969 | DBMET02969 | |
| 0.085 | 0.097 | 0.144 | Cystathionine beta-synthase inhibitor | 0.144 0.043 DBMET02968 0.119 0.059 DBMET02969 | DBMET02968 | |
| 0.056 | 0.068 | 0.069 | Beta 2 adrenoreceptor agonist | 0.069 0.021 DBMET02968 | DBMET02968 | |
| 0.035 | 0.049 | 0.041 | Opioid mu receptor agonist | 0.041 0.039 DBMET02968 | DBMET02968 | |
| 0.074 | 0.088 | 0.08 | Interleukin 5 antagonist | 0.08 0.074 DBMET02969 | DBMET02969 | |
| 0.136 | 0.153 | 0.151 | Aldehyde oxidase inhibitor | 0.151 0.138 DBMET02968 | DBMET02968 | |
| 0.107 | 0.125 | 0.124 | Vanilloid 1 agonist | 0.121 0.085 DBMET02968 0.124 0.079 DBMET02970 | DBMET02970 | |
| 0.045 | 0.066 | 0.329 | Selectin antagonist | 0.329 0.004 DBMET02969 0.249 0.008 DBMET02970 | DBMET02969 | |
| 0.04 | 0.07 | 0.074 | Alpha-mannosidase inhibitor | 0.074 0.014 DBMET02969 | DBMET02969 | |
| 0.072 | 0.103 | 0.093 | Creatine kinase inhibitor | 0.093 0.068 DBMET02968 | DBMET02968 | |
| 0.098 | 0.13 | 0.188 | Peroxidase inhibitor | 0.188 0.062 DBMET02968 | DBMET02968 | |
| 0.118 | 0.152 | 0.178 | Interleukin 6 antagonist | 0.178 0.056 DBMET02969 | DBMET02969 | |
| 0.017 | 0.051 | 0.028 | Vanilloid 2 agonist | 0.028 0.013 DBMET02969 | DBMET02969 | |
| 0.198 | 0.232 | 0.662 | Antibacterial | 0.326 0.117 DBMET02968 0.662 0.012 DBMET02969 0.263 0.165 DBMET02970 | DBMET02969 | |
| 0.025 | 0.068 | 0.069 | Antibiotic Aminoglycoside-like | 0.069 0.006 DBMET02969 | DBMET02969 | |
| 0.078 | 0.124 | 0.144 | Alkylator | 0.144 0.05 DBMET02969 | DBMET02969 | |
| 0.142 | 0.195 | 0.583 | Hypoglycemic | 0.583 0.009 DBMET02969 | DBMET02969 | |
| 0.067 | 0.121 | 0.247 | Expectorant | 0.247 0.013 DBMET02969 | DBMET02969 | |
| 0.022 | 0.082 | 0.047 | Phosphorylase inhibitor | 0.047 0.032 DBMET02969 | DBMET02969 | |
| 0.034 | 0.105 | 0.09 | Heparanase inhibitor | 0.09 0.005 DBMET02969 | DBMET02969 | |
| 0.06 | 0.132 | 0.091 | Triose-phosphate isomerase inhibitor | 0.091 0.058 DBMET02969 | DBMET02969 | |
| 0.01 | 0.097 | 0.082 | Sodium/glucose cotransporter 2 inhibitor | 0.082 0.004 DBMET02969 | DBMET02969 | |
| 0.012 | 0.101 | 0.07 | Sodium/glucose cotransporter inhibitor | 0.07 0.004 DBMET02969 | DBMET02969 | |
| 0.059 | 0.148 | 0.096 | NADH dehydrogenase inhibitor | 0.096 0.048 DBMET02969 | DBMET02969 | |
| 0.065 | 0.162 | 0.079 | T cell inhibitor | 0.079 0.068 DBMET02969 | DBMET02969 | |
| 0.035 | 0.136 | 0.077 | Na+ K+ transporting ATPase inhibitor | 0.077 0.054 DBMET02969 | DBMET02969 | |
| 0.054 | 0.163 | 0.113 | UDP-glucose 4-epimerase inhibitor | 0.113 0.049 DBMET02969 | DBMET02969 | |
| 0.072 | 0.189 | 0.13 | Interleukin 4 antagonist | 0.13 0.072 DBMET02968 0.124 0.08 DBMET02969 | DBMET02968 | |
| 0.021 | 0.139 | 0.096 | Protein 50S ribosomal subunit inhibitor | 0.096 0.014 DBMET02969 | DBMET02969 | |
| 0.059 | 0.179 | 0.184 | Beta glucuronidase inhibitor | 0.184 0.015 DBMET02969 | DBMET02969 | |
| 0.056 | 0.18 | 0.148 | DNA polymerase I inhibitor | 0.148 0.05 DBMET02969 | DBMET02969 | |
| 0.024 | 0.149 | 0.059 | Phosphofructokinase-1 inhibitor | 0.059 0.057 DBMET02969 | DBMET02969 | |
| 0.017 | 0.146 | 0.2 | Cholecystokinin B agonist | 0.2 0.004 DBMET02970 | DBMET02970 | |
| 0.082 | 0.227 | 0.175 | DNA repair enzyme inhibitor | 0.175 0.015 DBMET02969 | DBMET02969 | |
| 0.01 | 0.17 | 0.038 | Protein 30S ribosomal subunit inhibitor | 0.038 0.01 DBMET02969 | DBMET02969 | |
| 0.046 | 0.241 | 0.21 | Amylase inhibitor | 0.21 0.041 DBMET02969 | DBMET02969 | |
| 0.103 | 0.299 | 0.407 | Transcription factor NF kappa B inhibitor | 0.407 0.062 DBMET02969 | DBMET02969 | |
| 0.072 | 0.286 | 0.224 | Insulin secretagoues | 0.224 0.026 DBMET02969 | DBMET02969 | |
| 0.042 | 0.269 | 0.101 | Thioredoxin inhibitor | 0.101 0.047 DBMET02969 | DBMET02969 | |
| 0.004 | 0.244 | 0.126 | Cholecystokinin agonist | 0.126 0.004 DBMET02970 | DBMET02970 | |
| 0.117 | 0.366 | 0.203 | Histamine release inhibitor | 0.203 0.198 DBMET02969 | DBMET02969 | |
| 0.004 | 0.279 | 0.031 | Cholecystokinin B antagonist | 0.031 0.02 DBMET02970 | DBMET02970 | |
| 0.004 | 0.28 | 0.067 | Cholecystokinin A antagonist | 0.067 0.015 DBMET02970 | DBMET02970 | |
| 0.059 | 0.341 | 0.16 | DNA methylase inhibitor | 0.16 0.109 DBMET02969 | DBMET02969 | |
| 0.088 | 0.371 | 0.224 | Cholesterol antagonist | 0.224 0.144 DBMET02969 | DBMET02969 | |
| 0.005 | 0.317 | 0.035 | 1,3-Beta-glucan synthase inhibitor | 0.035 0.006 DBMET02970 | DBMET02970 | |
| 0.013 | 0.326 | 0.027 | Toll-Like receptor 4 agonist | 0.027 0.016 DBMET02969 | DBMET02969 | |
| 0.047 | 0.368 | 0.087 | Interleukin 12 antagonist | 0.087 0.079 DBMET02969 | DBMET02969 | |
| 0.004 | 0.332 | 0.041 | Cholecystokinin antagonist | 0.041 0.029 DBMET02970 | DBMET02970 | |
| 0.055 | 0.39 | 0.346 | Hepatoprotectant | 0.346 0.02 DBMET02969 | DBMET02969 | |
| 0.088 | 0.427 | 0.199 | Vasodilator, coronary | 0.199 0.183 DBMET02969 | DBMET02969 | |
| 0.017 | 0.368 | 0.091 | Topoisomerase II alpha inhibitor | 0.091 0.046 DBMET02969 | DBMET02969 | |
| 0.004 | 0.361 | 0.087 | Cholecystokinin A agonist | 0.087 0.004 DBMET02970 | DBMET02970 | |
| 0.03 | 0.396 | 0.058 | Lipocortins synthesis agonist | 0.058 0.039 DBMET02969 | DBMET02969 | |
| 0.042 | 0.419 | 0.414 | Free radical scavenger | 0.414 0.026 DBMET02969 | DBMET02969 | |
| 0.032 | 0.432 | 0.137 | Toll-Like receptor 4 antagonist | 0.137 0.029 DBMET02969 | DBMET02969 | |
| 0.071 | 0.473 | 0.426 | Immunomodulator | 0.426 0.037 DBMET02969 | DBMET02969 | |
| 0.024 | 0.442 | 0.055 | Adenine nucleotide translocase inhibitor | 0.055 0.04 DBMET02969 | DBMET02969 | |
| 0.009 | 0.469 | 0.081 | Elastase inhibitor | 0.081 0.016 DBMET02970 | DBMET02970 | |
| 0.017 | 0.506 | 0.101 | ATPase (Vacuolar H+) inhibitor | 0.101 0.038 DBMET02969 | DBMET02969 | |
| 0.069 | 0.567 | 0.68 | Cyclophilin D inhibitor | 0.68 0.016 DBMET02969 | DBMET02969 | |
| 0.027 | 0.563 | 0.445 | Antioxidant | 0.445 0.027 DBMET02969 | DBMET02969 | |
| 0.037 | 0.585 | 0.397 | Immunosuppressant | 0.397 0.064 DBMET02969 | DBMET02969 | |
| 0.063 | 0.637 | 0.623 | Antiinflammatory | 0.623 0.047 DBMET02969 0.291 0.224 DBMET02970 | DBMET02969 | |
| 0.004 | 0.578 | 0.126 | Antineoplastic antibiotic | 0.126 0.037 DBMET02969 | DBMET02969 | |
| 0.011 | 0.65 | 0.168 | Lipid peroxidase inhibitor | 0.168 0.056 DBMET02969 | DBMET02969 | |
| 0.016 | 0.676 | 0.159 | Vasodilator | 0.159 0.144 DBMET02969 | DBMET02969 | |
| 0.066 | 0.729 | 0.128 | CC chemokine 6 receptor antagonist | 0.128 0.079 DBMET02969 | DBMET02969 | |
| 0.015 | 0.69 | 0.26 | Nitric oxide antagonist | 0.26 0.049 DBMET02969 | DBMET02969 | |
| 0.01 | 0.71 | 0.058 | Glucose-6-phosphate translocase inhibitor | 0.058 0.026 DBMET02969 | DBMET02969 | |
| 0.024 | 0.746 | 0.094 | Transcription factor NF kappa B stimulant | 0.094 0.045 DBMET02969 | DBMET02969 | |
| 0.006 | 0.742 | 0.099 | Topoisomerase I inhibitor | 0.099 0.071 DBMET02969 | DBMET02969 | |
| 0.006 | 0.742 | 0.116 | Estrogen receptor beta antagonist | 0.116 0.036 DBMET02968 | DBMET02968 | |
| 0.007 | 0.791 | 0.121 | Estrogen antagonist | 0.121 0.054 DBMET02968 | DBMET02968 | |
| 0.002 | 0.808 | 0.146 | Estrone sulfatase inhibitor | 0.146 0.004 DBMET02970 | DBMET02970 | |
| 0.005 | 0.828 | 0.096 | Topoisomerase II inhibitor | 0.096 0.09 DBMET02969 | DBMET02969 | |
| 0.014 | 0.846 | 0.431 | Apoptosis agonist | 0.431 0.099 DBMET02969 | DBMET02969 | |
| 0.023 | 0.902 | 0.134 | NOS3 expression enhancer | 0.134 0.091 DBMET02969 | DBMET02969 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |